Scil Proteins GmbH Establishes Business Development Infrastructure in North America
Published: Mar 14, 2012
Scil Proteins is delighted to announce that it has appointed Garry Merry to lead this new organization. Mr. Merry has a wealth of experience supporting the business development efforts of several small protein engineering, biopharmaceutical and drug discovery companies in North America, including Sloning Biotechnologies GmbH, Isogenica Ltd. and TerraSep LLC. Mr. Merry has also held senior executive positions at several leading life science companies, including Waters, Applied Biosystems and Qiagen.
“A local presence to interface directly with our customers, collaborators and partners in North America is vital to ensure our continued success and the expansion of our business on a global basis,” said Frank Ubags, COO of Scil Proteins. “With his background in protein engineering and separations, Garry Merry is ideally positioned to help us achieve our growth objectives.”
Commenting on his appointment, Garry Merry added, “My career has always revolved around proteins, going back as far back as 1986, when I helped found the Protein Society. That being said, I am pleased that Scil Proteins has asked me to support their business efforts here in North America and I am confident that the Company’s world-class GMP facility in Germany will be extremely busy going forward.”
Scil Proteins’ powerful Affilin® drug discovery platform, which is available for out-licensing to biotechnology and pharmaceutical companies, will continue to be supported out of the Company’s corporate headquarter in Halle, Germany. In addition, Scil Proteins’ corporate headquarters will remain responsible for all other activities related to the Company’s CMO business outside of the US and Canada.
About Scil Proteins
Scil Proteins is a biopharmaceutical company working with industry partners in the development and manufacture of protein therapeutics and diagnostics as well as discovering and developing proprietary Affilin® molecules. The Company has a longstanding expertise in protein production and development and offers GMP contract biomanufacturing and process development to biotech and pharma companies. With state of the art equipment and a particular expertise at refolding proteins, Scil Proteins has an excellent track record in supplying a top level support for its partners. Scil Proteins has supported a number of different companies in process development and biomanufacturing. Scil Proteins also has a discovery platform that is a fully patent protected screening technology for the identification of target-specific Affilin® molecules using advanced selection systems. Affilin® molecules are therapeutics and diagnostics based on a scaffold derived from the human protein Ubiquitin to form highly stable molecules with strong binding specificity and low immunogenicity. Scil Proteins has generated a pipeline of Affilin® therapeutics targeting cancer. Scil Proteins is a well-established private company located in Halle, Germany.
To learn more about Scil Proteins, please visit www.scilproteins.com.
Scil Proteins GmbH
t: +49 (0) 345 27 99 63 61
t: (Germany) +49 (0) 89 52 05 92 12
Scil Proteins North America
Business Development Consultant
t: +1 510 846 0736